Literature DB >> 24014291

The CLL cell microenvironment.

Jan A Burger1.   

Abstract

Cross talk between CLL cells and accessory stromal cells in specialized tissue microenvironments, such as the secondary lymphoid organs, favors CLL progression by promoting malignant B cell growth and drug resistance. Disrupting the cross talk between CLL cells and their milieu is an attractive, novel strategy for treating CLL patients. This chapter summarizes current knowledge about cellular and molecular interactions between CLL cells and their supportive tissue microenvironment and the therapeutic targets that are emerging, focusing on the CXCR4-CXCL12 axis and small molecule inhibitors that are targeting the B cell receptor-associated kinases SYK, BTK, and PI3Kδ. Clinically relevant aspects of these new therapeutics will be discussed, along with an outlook into future biologically oriented therapeutic strategies. The rapid progress in dissecting the CLL microenvironment and the promising early results of these new targeted treatments in CLL indicate that CLL has become a role model for microenvironment-dependent cancers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24014291     DOI: 10.1007/978-1-4614-8051-8_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

Review 1.  The molecular pathogenesis of chronic lymphocytic leukaemia.

Authors:  Giulia Fabbri; Riccardo Dalla-Favera
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

2.  Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL.

Authors:  Deyan Yordanov Yosifov; Irina Idler; Nupur Bhattacharya; Michaela Reichenzeller; Viola Close; Daria Ezerina; Annika Scheffold; Billy Michael Chelliah Jebaraj; Sabrina Kugler; Johannes Bloehdorn; Jasmin Bahlo; Sandra Robrecht; Barbara Eichhorst; Kirsten Fischer; Anja Weigel; Hauke Busch; Peter Lichter; Hartmut Döhner; Tobias P Dick; Stephan Stilgenbauer; Daniel Mertens
Journal:  Leukemia       Date:  2019-07-12       Impact factor: 11.528

3.  Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib.

Authors:  Noelia Purroy; Yuzhou Evelyn Tong; Camilla K Lemvigh; Nicoletta Cieri; Shuqiang Li; Erin M Parry; Wandi Zhang; Laura Z Rassenti; Thomas J Kipps; Susan L Slager; Neil E Kay; Connie Lesnick; Tait D Shanafelt; Paolo Ghia; Lydia Scarfò; Kenneth J Livak; Peter V Kharchenko; Donna S Neuberg; Lars Rønn Olsen; Jean Fan; Satyen H Gohil; Catherine J Wu
Journal:  Blood       Date:  2022-04-07       Impact factor: 25.476

4.  LMW-PTP targeting potentiates the effects of drugs used in chronic lymphocytic leukemia therapy.

Authors:  Nagaja Capitani; Giulia Lori; Paolo Paoli; Laura Patrussi; Arianna Troilo; Cosima T Baldari; Giovanni Raugei; Mario Milco D'Elios
Journal:  Cancer Cell Int       Date:  2019-03-21       Impact factor: 5.722

Review 5.  Molecular Players in Hematologic Tumor Cell Trafficking.

Authors:  Javier Redondo-Muñoz; Angeles García-Pardo; Joaquin Teixidó
Journal:  Front Immunol       Date:  2019-02-06       Impact factor: 7.561

6.  Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.

Authors:  Michael Steurer; Marco Montillo; Lydia Scarfò; Francesca R Mauro; Johannes Andel; Sophie Wildner; Livio Trentin; Ann Janssens; Sonja Burgstaller; Anna Frömming; Thomas Dümmler; Kai Riecke; Matthias Baumann; Diana Beyer; Stéphanie Vauléon; Paolo Ghia; Robin Foà; Federico Caligaris-Cappio; Marco Gobbi
Journal:  Haematologica       Date:  2019-05-16       Impact factor: 9.941

7.  Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia.

Authors:  Begüm Alankus; Veronika Ecker; Nathalie Vahl; Martina Braun; Wilko Weichert; Stephan Macher-Göppinger; Torben Gehring; Tanja Neumayer; Thorsten Zenz; Maike Buchner; Jürgen Ruland
Journal:  J Exp Med       Date:  2021-02-01       Impact factor: 14.307

8.  EphrinA4 plays a critical role in α4 and αL mediated survival of human CLL cells during extravasation.

Authors:  Miguel A Flores; Paula Fortea; Eva M Trinidad; Dolores García; Gloria Soler; Francisco J Ortuño; Agustín G Zapata; Luis M Alonso-Colmenar
Journal:  Oncotarget       Date:  2016-07-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.